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BACKGROUND: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in
patients with oesophagogastric cancer, but leads to high rates of haematological toxicity. Weekly docetaxel is associated with less
haematological toxicity. This randomised phase II study tested weekly docetaxel-based combination chemotherapy regimens, with
the aim of maintaining their activity while reducing toxicity.
METHODS: Patients with histologically confirmed metastatic oesophageal or gastric carcinoma were randomised to receive weekly
docetaxel (30mgm
 2) on days 1 and 8, cisplatin (60mgm
 2) on day 1, and 5-fluorouracil (200mgm
 2 per day) continuously, every
3 weeks (weekly TCF, wTCF); or docetaxel (30mgm
 2) on days 1 and 8 and capecitabine (1600mgm
 2 per day) on days 1–14,
every 3 weeks (weekly TX, wTX).
RESULTS: A total of 106 patients were enrolled (wTCF, n¼50; wTX, n¼56). Response rates, the primary end point, were 47% with
wTCF and 26% with wTX. Rates of febrile neutropenia were low in each arm. Median progression-free and overall survival times
were 5.9 and 11.2 months for wTCF and 4.6 and 10.1 months for wTX, respectively.
CONCLUSION: Weekly TCF and TX have encouraging activity and less haematological toxicity than TCF administered 3-weekly.
Weekly docetaxel-based combination regimens warrant further evaluation in this disease.
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Oesophagogastric cancer is a major public health problem and is
the fourth highest cause of cancer-related mortality globally
(Kamangar et al, 2006). Although chemotherapy can improve
survival and maintain quality of life for patients with advanced
oesophagogastric cancer (Glimelius et al, 1995), optimal chemo-
therapy for this disease has not been defined.
A recent randomised phase III study showed that adding
docetaxel to cisplatin and 5-FU (TCF) improved response rates,
progression-free survival (PFS) times, and overall survival (OS)
(Van Cutsem et al, 2006). Although the TCF regimen improved
clinical outcomes, it was also associated with toxicity, particularly
that related to myelosuppression, with a 29% incidence of febrile
neutropenia or neutropenic infection.
Several studies have compared weekly with 3-weekly treatment
with docetaxel. Weekly docetaxel is associated with minimal
myelosuppression, but with a higher rate of cumulative fatigue,
tearing, and nail toxicity (Engels and Verweij, 2005). We postulated
that combination regimens using weekly docetaxel may provide
palliative benefit for patients with advanced oesophagogastric
cancer. As there is potential synergy between docetaxel and
capecitabine (Nadella et al, 2002), thought to be mediated through
activation of thymidine phosphorylase by docetaxel, we also aimed
to explore the activity of a doublet regimen, thereby avoiding the
potential toxicity of cisplatin. We therefore evaluated two novel
regimens based on weekly docetaxel in a randomised phase II
design called the ATTAX study (A randomised phase Two study
evaluating a weekly schedule of doceTAXel with cisplatin and 5-FU
(weekly TCF, wTCF) or with capecitabine (weekly TX, wTX) in
advanced oesophagogastric cancer).
PATIENTS AND METHODS
Eligibility
The ATTAX study was conducted according to a protocol reviewed
and approved by the Australasian Gastro-Intestinal Trials Group
(AGITG), and reviewed and approved by the Human Research
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sEthics Committee of each participating institution. All patients
provided written informed consent.
Patients were eligible if they were 18 years of age or older with a
histologically confirmed diagnosis of oesophageal, gastric, or
oesophagogastric junction carcinoma (squamous, adenocarcinoma
or undifferentiated), and of metastatic disease that was uni-
dimensionally measurable according to the Response Evaluation
Criteria in Solid Tumours (RECIST). Inclusion of oesophageal,
oesophagogastric, and gastric cancers is justified by data showing
comparable outcomes for these diseases (Chau et al, 2009a).
Similarly, outcomes for patients with advanced squamous cell
carcinoma are not significantly different from those for patients
with adenocarcinoma (Chau et al, 2007). Patients were not allowed
to have had previous anticancer treatment, except for adjuvant
radiotherapy or chemotherapy completed at least 12 months
before. Further inclusion criteria included WHO performance
status (PS) of 0, 1, or 2 (PS2 patients were required to have serum
albumin of at least 30gl
 1); adequate bone marrow function,
including platelets (4100 10
9 cells per l) and neutrophils
(41.5 10
9 cells per l); normal renal function, including normal
serum creatinine and calculated creatinine clearance of at least
50mlmin
 1; and adequate hepatic function, including serum total
bilirubin o1.25 upper limit of normal range, alanine transami-
nase or aspartate transaminase o2.5 upper limit of normal
range, and alkaline phosphatase o5 upper limit of normal
range. In addition, patients had to be able to swallow tablets, have
a life expectancy of more than 12 weeks, and have no concurrent
uncontrolled medical conditions and no previous malignant
disease other than non-melanotic skin cancer or carcinoma
in situ of the uterine cervix or other cancers treated with curative
intent at least 5 years previously and without evidence of relapse.
Patients were required to have a negative pregnancy test and had
to agree to practise adequate contraception.
Exclusion criteria included medical or psychiatric conditions
that compromised the patient’s ability to give informed consent or
comply with the study protocol, metastatic disease of the central
nervous system, pregnancy or breastfeeding, clinical evidence of
peripheral neuropathy of 4grade II, and significant deafness or
uncontrolled tinnitus. Patients with any uncontrolled concurrent
medical condition, known malabsorption syndrome, or who had
participated in an investigational drug study within 4 weeks were
also excluded from participation in the study.
Randomisation, stratification and treatment
The ATTAX study was a randomised, phase II, open-label,
multicentre study of wTCF or wTX. Randomisation was carried
out centrally at the coordinating centre, and patients were
stratified by WHO PS (0, 1 vs 2) and institution.
Patients were randomly assigned in equal proportions to
receive either docetaxel (Taxotere; Sanofi-Aventis, Paris, France)
(30mgm
 2) on days 1 and 8, cisplatin (60mgm
 2) on day 1, and
5-fluorouracil (200mgm
 2 per day) by continuous infusion, every
3 weeks (wTCF); or docetaxel (30mgm
 2) on days 1 and 8 and oral
capecitabine (Xeloda; Roche, Basel, Switzerland) (800mgm
 2)
twice daily on days 1–14, every 3 weeks (wTX). The dosages were
selected for the combination regimens with reference to earlier
phase I or II studies (Chen et al, 2002; Lee et al, 2006; Mrozek et al,
2006). Premedication of dexamethasone (8mg) was given before
docetaxel administration, and cisplatin hydration was given
according to each investigator’s routine practice. Dose-modifica-
tion criteria were defined in the protocol. Treatment continued for
eight cycles in the absence of disease progression, any request by
the patient or physician to discontinue therapy, unacceptable
toxicity, pregnancy, or serious systemic allergic reaction to any of
the study drugs. At the investigator’s discretion, patients with no
disease progression or grade III or IV toxicity could continue
beyond eight cycles. Patients in the wTCF arm experiencing
auditory or peripheral neurotoxicity or renal impairment, thought
to be related to cisplatin, were allowed to substitute carboplatin
for cisplatin.
Evaluation and outcomes
Before randomisation, each patient was assessed by complete
physical examination, full blood count, clotting profile, blood
biochemistry, tumour markers (carcinoembryonic antigen (CEA)
and carbohydrate antigen (CA 19.9)), 12-lead electrocardiogram,
contrast-enhanced CT scan of the thorax, abdomen, and pelvis,
and a pregnancy test for women of child-bearing potential.
Subsequently, complete physical examination, blood bio-
chemistry, and a toxicity and adverse event assessment were
repeated before each cycle began; a full blood count was repeated
before every docetaxel infusion. A tumour marker assessment and
contrast-enhanced CT scan of the thorax, abdomen, and pelvis
were repeated at the end of every second treatment cycle, then
12-weekly until disease progression.
Toxicity was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI CTCAE),
version 3.0.
Quality of life was assessed using the European Organisation for
Research and Treatment of Cancer Quality-of-Life Questionnaire
(QLQ) C30, version 3.0 (01 February 2003), together with the
oesophageal-specific module (OES 18) or the gastric module (STO
22). Patients with tumours involving the oesophagogastric junction
completed the oesophageal module. Questionnaires were completed
3-weekly for the first 12 weeks, then 6-weekly until the completion of
chemotherapy, then 12-weekly until disease progression.
After permanent discontinuation of study treatment, patients
were assessed for progression status (until documented disease
progression), commencement of non-study treatment, and survival
status every 12 weeks until death.
Statistical analysis
The primary clinical end point of the study was response rate, as
assessed by RECIST. Secondary end points were OS, PFS,
treatment-related toxicity, disease-associated symptoms, and
quality of life.
Although randomisation was used to allocate patients to either
the wTCF or wTX arm, no comparisons between treatment
regimens were planned. The purpose of randomisation was to
reduce bias due to patient selection into either treatment arm.
Overall survival was measured from the date of randomisation
to the date of death from any cause. Progression-free survival was
measured from the date of randomisation to the first evidence of
disease progression or the date of death if progression was not
previously documented. Time-to-event parameters were estimated
using the Kaplan–Meier method. Disease-associated symptoms
were derived from the QLQs.
The study used Simon’s two-stage design in each arm. For each
arm, the first stage required more than five confirmed responses
(complete or partial) in the first 21 patients. The second stage
involved complete accrual to 50 patients per treatment arm.
Each treatment was expected to achieve a response rate of 37%,
which was considered clinically worthwhile and consistent with
previous studies using docetaxel. The lowest limit of therapeutic
effect considered to be of interest was a response rate of 17%. On
the basis of these limits, and 90% power and a 95% confidence
level, 13 or more responses (complete or partial) per treatment
arm were required to determine that a regimen was active.
Study monitoring
An independent data and safety monitoring board reviewed the
safety data after 15 and 25 patients had been enrolled in each
ATTAX: weekly docetaxel-based chemotherapy
NC Tebbutt et al
476
British Journal of Cancer (2010) 102(3), 475–481 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
streatment arm. The tumour response of each patient was centrally
reviewed by the lead study clinician and a clinician independent of
the study. A total of 7% of patients at 14% of institutions were
audited by an independent auditor. No significant protocol
discrepancies or deviations were noted.
RESULTS
Patient characteristics
Between June 2004 and May 2006, 106 patients were randomised
(wTCF, 50 patients; wTX, 56 patients) from 19 institutions in
Australia and 1 in New Zealand. Two patients were ineligible (no
measurable disease), two patients did not commence treatment
(one died and one withdrew consent), and two patients did not
have any subsequent valid RECIST tumour assessments (Figure 1).
The 100 patients who commenced treatment, who had measurable
disease, and were assessed according to RECIST, were included in
the response-rate analysis. All 106 patients randomised to the
study were included in the PFS and OS analyses on an intention-to-
treat basis. The 104 patients who commenced study treatment were
included in the toxicity analyses. The 99 patients who completed
the QLQs were included in the disease-related symptoms and
quality-of-life analyses.
Baseline characteristics were well balanced between the
treatment arms (Table 1).
50 Recruited 
49 Treated
47 Response rate
measured
45 Progression
status measured
49 Safety and
toxicity measured
22 Response
duration measured
50 Progression-free
and overall
survival measured
1 no measurable
disease
1 response not
properly
assessed
1 died
1 non-protocol
treatment
1 withdrew
consent for
scans
47 Quality of life
measured
Randomisation
wTCF
56 Recruited
55 Treated
53 Response rate
measured
52 Progression
status measured
55 Safety and
toxicity measured
14 Response duration
measured
56 Progression-free
and overall survival
measured
1 no measurable
disease
1 response not
properly
assessed
1 consent
withdrawn
1 died without
 progression
52 Quality of life
measured
wTX
Figure 1 Enrolment and analysis in the ATTAX study. wTCF¼weekly docetaxel, plus cisplatin and 5-fluorouracil; wTX¼weekly docetaxel plus
capecitabine.
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The median number of cycles delivered per patient was 6 cycles of
wTCF (range, 1–8) and 5 cycles of wTX (range, 1–14). Dose
intensities compared with the starting dosages in the wTCF arm
were docetaxel, 92%; cisplatin, 91%; and 5-FU, 98%. In the wTX
arm, they were docetaxel, 98% and capecitabine, 93%. Four
patients in the wTCF arm had cisplatin-related toxicity and
subsequently substituted carboplatin for cisplatin. Treatment
delays of more than 1 week occurred for 10 patients (29%) in
the wTCF arm and for 4 patients (7%) in the wTX arm.
Efficacy
Interim response analysis was carried out after 21 patients were
recruited to each treatment arm. There were 11 partial responses in
the wTCF arm and 5 partial responses in the wTX arm, meeting the
criterion of at least 5 responses per treatment arm for the study to
continue.
A total of 106 patients were recruited, and the final response
analysis was performed 12 months after the last patient was
randomised. Of the 47 patients assessable for response in the
wTCF arm, 2 had complete response, 20 had partial response, and
18 had stable disease. Of the 53 assessable patients in the wTX arm,
none had complete response, 14 had partial response, and 28 had
stable disease (Table 2). The confirmed overall response rates
were 47% (95% CI, 32–62%) for wTCF and 26% (95% CI, 15–40%)
for wTX.
At the median follow-up time of 40.7 months, 92 patients had
progressed, two could not be assessed for progression (one
commenced non-protocol treatment before progression and one
withdrew consent for further CT scans), whereas four patients in
the wTCF arm and one patient in the wTX arm had not progressed.
The median durations for response were 6.45 months for wTCF
and 6.74 months for wTX.
At the time of analysis, 98 patients had died. Median PFS times
were 5.9 months for wTCF and 4.6 months for wTX (Figure 2).
Median OS times were 11.2 months for wTCF and 10.1 months for
wTX (Figure 3).
Toxicity
Toxicity in the 104 patients who commenced treatment is
summarised in Table 3. Three patients on wTCF and one on
wTX had grade III febrile neutropenia; both rates are significantly
Table 1 Patient and cancer baseline characteristics
wTCF (n¼50) wTX (n¼56)
Characteristic No. % No. %
Age (years)
Mean (standard deviation) 60.5 (11.5) 59.1 (10.8)
Range 35–82 32–79
Gender
Male 42 84 42 75
WHO performance status
02 1 4 2 3 1 5 5
12 8 5 6 2 3 4 1
21 2 2 4
Primary site
Oesophagus 11 22 20 36
Oesophagogastric junction 13 26 13 23
Gastric 26 52 23 41
Disease status
Local recurrence 2 4 5 9
Histology
Squamous cell carcinoma 2 4 9 16
Adenocarcinoma 47 94 45 80
Undifferentiated 1 2 2 4
Sites of metastasis
Nodal 30 61 41 73
Liver 25 51 28 50
Pulmonary 7 15 15 27
Peritoneal 10 20 6 11
Bone 5 10 7 13
Number of metastatic organs
12 4 4 8 2 1 3 8
21 9 3 8 2 4 4 3
33 6 6 1 1
43 6 5 9
RMH prognostic index
Good 12 24 19 34
Moderate 37 74 36 64
Poor 1 2 1 2
Received before adjuvant treatment
Adjuvant radiotherapy 2 4 1 2
Abbreviations: WHO¼World Health Organization; wTCF¼weekly docetaxel plus
cisplatin and 5-fluorouracil; wTX¼weekly docetaxel plus capecitabine.
Table 2 Best overall response rates in 100 evaluable patients
wTCF (%)
(95% CI)
wTX (%)
(95% CI)
Tumour response (n¼47) (n¼53)
Confirmed complete response 4 0
Confirmed partial response 43 26
Confirmed complete or partial response 47 (32–62) 26 (15–40)
Stable disease 38 53
Progressive disease 15 21
Abbreviations: wTCF¼weekly docetaxel plus cisplatin and 5-fluorouracil;
wTX¼weekly docetaxel plus capecitabine.
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Figure 2 Kaplan–Meier curves of progression-free survival for advanced
oesophagogastric cancer patients treated with weekly docetaxel, plus
cisplatin and 5-fluorouracil (wTCF; n¼50), or weekly docetaxel with
capecitabine (wTX; n¼56).
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chemotherapy regimens. The most significant common adverse
events in the wTCF arm were grade III or IV diarrhoea, grade III or
IV fatigue, grade III stomatitis, grade III anorexia, and grade III
nausea. The most significant common adverse events in the wTX
arm were grade III nausea, grade III vomiting, grade III diarrhoea,
grade III anorexia, and grade III fatigue.
Mortality from any cause at 60 days was 6% in the wTCF arm
(three patients; 95% CI, 0.7–11.3%) and 0% in the wTX arm (95%
CI, 0–6%). There were no treatment-related deaths.
Disease-associated symptoms and quality of life
Improvement in a specific disease-associated symptom or an
aspect of quality of life was defined as an increase of 10 points or
more for that questionnaire item for more than 3 weeks. For wTCF
and wTX, improvement in global health and quality of life was seen
in 30% and 35% of patients, in nausea and vomiting in 30% and
31%, in fatigue in 36% and 46%, and in pain in 47% and 50%,
respectively. The most striking improvement was in dysphagia in
patients with oesophageal disease, among whom 71% and 70%
treated with wTCF and wTX improved, respectively, compared
with 46% and 41% of patients with gastric disease, respectively.
DISCUSSION
This randomised phase II study has shown that it is feasible to
develop combination chemotherapy regimens incorporating
weekly docetaxel for advanced oesophagogastric cancer. There is
clear evidence that docetaxel has non-cross-resistant activity in
advanced oesophagogastric cancer. Docetaxel has efficacy as a
single agent after failure of platinum and fluoropyrimidines, as
well as additive activity when used in combination with cisplatin
and 5-FU (Cascinu et al, 2001; Van Cutsem et al, 2006). However,
significant myelosuppression with 3-weekly administration poses a
major problem for the development of combination chemotherapy
regimens, because the myelosuppressive effects add to the
toxicities of other chemotherapy agents. The most striking change
in the safety profile of the weekly docetaxel-based combination
regimens used in this study was a substantially lower rate of
myelosuppression and complicated neutropenia compared with
that of 3-weekly TCF (Van Cutsem et al, 2006). This occurred
despite the somewhat older population of patients (the median age
in both arms was over 60 years) in this study, whereas older
patients have higher rates of toxicity with 3-weekly TCF (Van
Cutsem et al, 2006). Cumulative toxicities related to docetaxel,
such as fatigue and tearing, did not occur at high frequency in
either treatment arm. In addition to modifying the docetaxel
schedule, both regimens involved an altered fluoropyrimidine
schedule (either continuous-infusion 5FU or capecitabine) com-
pared with 3-weekly TCF, which used a 4-day infusion of high-dose
5FU. This may also have contributed to lower rates of
myelosuppression, as other studies have shown more manageable
rates of haematological toxicities with protracted infusion
schedules of 5FU (Thuss-Patience et al, 2005).
We showed clear evidence of efficacy of both regimens, with PFS
and OS times that seem promising. Although cross-study
comparisons are problematic, the population enrolled did not
seem to have more favourable demographic features than those
in the study by Van Cutsem et al, (2006); hence, an OS of over
Number at risk
wTCF
wTX
50
56
38
43
24
19
15
8
9
4
Months from randomisation
0 6 12 18 24
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
0.0
0.2
0.4
0.6
0.8
1.0
Median OS:
        wTCF: 11.2 months
        wTX:   10.1 months    
wTX
wTCF 
Figure 3 Kaplan–Meier curves of overall survival for advanced
oesophagogastric cancer patients treated with weekly docetaxel along
with cisplatin and 5-fluorouracil (wTCF; n¼50), or weekly docetaxel with
capecitabine (wTX; n¼56).
Table 3 Haematological and non-haematological adverse events (NCI CTCAE, version 3.0)
wTCF (n¼49) wTX (n¼55)
Type of adverse event Grade III, IV or V; No. (%) All grades; No. (%) Grade III, IV or V; No. (%) All grades; No. (%)
Infection with normal neutrophils 7 (14) 14 (29) 4 (7) 23 (42)
Febrile neutropenia 3 (6) 3 (6) 1 (2) 1 (2)
Anorexia 9 (18) 33 (67) 5 (9) 28 (51)
Nausea 8 (16) 38 (78) 8 (15) 39 (71)
Vomiting 6 (12) 23 (47) 5 (9) 22 (40)
Diarrhoea 11 (22) 30 (61) 5 (9) 27 (49)
Stomatitis 9 (18) 31 (63) 1 (2) 18 (33)
Alopecia 0 (0) 30 (61) 0 (0) 27 (49)
Rash: hand–foot skin reaction or PPE 4 (8) 16 (33) 3 (5) 25 (45)
Allergic reaction or hypersensitivity 0 (0) 1 (2) 0 (0) 2 (4)
Fatigue 9 (18) 45 (92) 5 (9) 47 (85)
Nail changes 0 (0) 12 (24) 2 (4) 27 (49)
Watery eyes (tearing) 0 (0) 12 (24) 0 (0) 18 (33)
Neuropathy: motor 1 (2) 1 (2) 0 (0) 4 (7)
Neuropathy: sensory 0 (0) 14 (29) 1 (2) 16 (29)
Neutrophil count ( 10
9 cells per l) 5 (10) 24 (49) 1 (2) 13 (24)
Platelet count ( 10
9 cells per l) 0 (0) 1 (2) 0 (0) 1 (2)
Abbreviations: NCI CTCAE¼National Cancer Institute Common Terminology Criteria for Adverse Events; wTCF¼weekly docetaxel plus cisplatin and 5-fluorouracil;
wTX¼weekly docetaxel plus capecitabine.
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s10 months in each arm is encouraging. A recent evaluation of over
1000 patients with advanced oesophagogastric cancer identified
several prognostic factors affecting survival outcomes (Chau et al,
2004) (the Royal Marsden Hospital Prognostic Index), which have
been validated in a subsequent data set (Chau et al, 2009b). Most
patients in each arm in this study had moderate risk factors,
previously associated with OS times of 8.6 months, reinforcing the
finding that the regimens were clinically active. Palliative benefit
was also shown by the improvement in relevant disease-related
symptoms, as determined by QLQs.
Several studies in advanced oesophagogastric cancer have
shown the activity of docetaxel and capecitabine doublets (Chun
et al, 2005; Kim et al, 2005; Lorenzen et al, 2005), although this is
not universal (Orditura et al, 2006). As a randomised phase II
study, our protocol was not powered for direct efficacy compar-
isons between the two arms. Nevertheless, the wTCF triplet
regimen had the most promising clinical efficacy, especially in
terms of response rates, and also for PFS and OS. Although the
wTCF triplet was tolerable, it is notable that the improved efficacy
was associated with higher rates of grade III/IV diarrhoea,
stomatitis, fatigue, and febrile neutropenia than the wTX doublet.
A similarly designed weekly docetaxel-based triplet was associated
with a comparable toxicity profile and encouraging efficacy in a
population in which almost half of the patients had locally
advanced disease only (Lorenzen et al, 2007). Other studies have
shown similar trends for greater activity from a triplet regimen
than from a doublet regimen in advanced gastric cancer
(Ajani et al, 2005; Roth et al, 2007). In other diseases, such as
colorectal cancer or breast cancer, it is common to sequence
doublet therapy or even monotherapy regimens. This may not be
so effective an approach for advanced oesophagogastric cancer, as
patients often have significant tumour-related symptoms at
diagnosis, requiring regimens with the highest levels of activity
to achieve significant palliative benefit. Furthermore, for those
patients with locally advanced disease (without overt metastatic
disease), regimens that result in high response rates may achieve
tumour downstaging, thereby facilitating subsequent resection
(Lorenzen et al, 2007).
In recent years, oral fluoropyrimidines have been evaluated in
oesophagogastric cancer. Capecitabine has been shown to have
equivalent activity to 5-FU, with a different safety profile
(Cunningham et al, 2008). It is likely that modification of the
wTCF regimen by substituting an oral fluoropyrimidine for 5-FU
would maintain activity, while potentially improving safety and
convenience.
Novel biological targeted agents, such as bevacizumab,
cetuximab, and panitumumab, have also improved outcomes in
a range of cancers including colorectal, breast, and lung cancer
(Hurwitz et al, 2004; Sandler et al, 2006; Jonker et al, 2007; Miller
et al, 2007; Van Cutsem et al, 2007). Some of these agents are
currently being evaluated in advanced oesophagogastric cancer.
Weekly docetaxel-based chemotherapy provides a useful chemo-
therapy backbone for evaluation of targeted agents, and the
AGITG is currently evaluating the efficacy and safety of adding
the epidermal growth factor receptor-targeted antibody, panitu-
mumab, to wTCF chemotherapy as treatment for this disease.
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